NCT00557037View on ClinicalTrials.gov

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

November 30, 2007

Study Completion Date

November 30, 2009

Conditions

Prostate Cancer

Interventions

DRUG

Phenoxodiol

Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months

Trial Locations (2)

06520

Yale Cancer Center, New Haven

06516

VA Connecticut Healthcare System, West Haven

Sponsors

Lead Sponsor

MEI Pharma, Inc.

All Listed Sponsors

lead

MEI Pharma, Inc.

INDUSTRY

NCT00557037 - A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer | Biotech Hunter | Biotech Hunter